Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06159335 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

18F-FLUC PET/MR in Patients With Brain Mets

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jun 2026 to Jun 2027v12
  2. Re-verified, no change to tracked fieldsv11
  3. Primary and study completion dates: Dec 2025 to Jun 2026v10
  4. Primary endpoints: 2 to 1
    • Study title revised
    • Eligibility criteria expanded, about 2 words
    v9
  5. Eligibility criteria expanded, about 42 wordsv8
Show 6 earlier versionsHide 6 earlier versions
  1. Site contact updatedv7
  2. Primary and study completion dates: Dec 2024 to Dec 2025v6
  3. Eligibility criteria expanded, about 74 wordsv5
  4. Eligibility criteria expanded, about 4 wordsv4
  5. Start date changed from estimate of Dec 2023 to Jan 10, 2024v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to use new imaging methods to help in finding out whether the imaging shows that there is a tumor in people with a brain metastasis. The main question it aims to answer is whether positron emission tomography (PET) and magnetic resonance imaging (MRI) find cancerous tissue better than other types of imagining. Participants will undergo a single PET/MRI scan, followed by a separate MRI scan with a tracer. Study participation will last about 3 hours.
Trial Details
NCT Number NCT06159335
Lead Sponsor University of Wisconsin, Madison
Collaborators: Blue Earth Diagnostics
Conditions
(from sponsor)		 Brain Metastasis, Radiation Therapy, Immunotherapy, Active
Related terms Brain Neoplasms, Motor Activity
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov